DAFFINÀ, MARIA GRAZIA
 Distribuzione geografica
Continente #
EU - Europa 169
NA - Nord America 86
AS - Asia 23
Totale 278
Nazione #
US - Stati Uniti d'America 86
IT - Italia 70
IE - Irlanda 49
SE - Svezia 14
GB - Regno Unito 11
FR - Francia 8
CN - Cina 4
FI - Finlandia 4
IQ - Iraq 4
SG - Singapore 4
VN - Vietnam 4
ES - Italia 3
DE - Germania 2
QA - Qatar 2
RU - Federazione Russa 2
TW - Taiwan 2
UA - Ucraina 2
AT - Austria 1
BE - Belgio 1
HK - Hong Kong 1
IN - India 1
NL - Olanda 1
PH - Filippine 1
PL - Polonia 1
Totale 278
Città #
Dublin 47
Siena 13
Fairfield 12
Southend 7
Ashburn 6
Chandler 5
Florence 5
Princeton 5
Woodbridge 5
Cagliari 4
Dong Ket 4
Labico 4
Palermo 4
Seattle 4
Sulaymaniyah 4
Cambridge 3
Helsinki 3
Málaga 3
Rome 3
Singapore 3
Doha 2
Fremont 2
Hamburg 2
Jacksonville 2
Moscow 2
New York 2
Paullo 2
Perugia 2
Pontassieve 2
Redwood City 2
San Diego 2
Sesto Fiorentino 2
Shanghai 2
Taipei 2
Verona 2
Wilmington 2
Amsterdam 1
Ann Arbor 1
Arlington 1
Beijing 1
Boardman 1
Brussels 1
Ferentino 1
Figline Valdarno 1
Graz 1
Haikou 1
Houston 1
Kilburn 1
Lappeenranta 1
London 1
Newark 1
Paris 1
Pistoia 1
Reggio Calabria 1
San Jose 1
San Mateo 1
Santa Maria 1
Scarperia 1
Sinalunga 1
Torino 1
Trieste 1
Warsaw 1
Washington 1
Totale 203
Nome #
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 120
PREDICTIVE BIOMARKER OF LONG TERM SURVIVAL IN MESOTHELIOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS 72
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 52
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 47
Totale 291
Categoria #
all - tutte 1.246
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.246


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202014 0 0 0 0 0 0 0 0 8 3 2 1
2020/202136 3 1 3 0 4 4 3 7 2 2 1 6
2021/202267 0 7 3 13 8 7 2 1 2 2 11 11
2022/202363 4 9 13 3 0 8 3 3 3 4 7 6
2023/2024108 12 4 5 4 3 21 29 8 2 2 2 16
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 291